lidocaine
Sources réglementaires consultées
Indications approuvées
- Soulagement temporaire et local du prurit léger de la zone vaginale externe dû à des irritants comme les sous-vêtements, savons ou déodorants, chez l’adulte et les filles de plus de 12 ans.
Contre-indications
Absolues
- Hypersensibilité à la lidocaïne, aux anesthésiques locaux apparentés de type amide ou à l’un des excipients.
- Filles de moins de 3 ans.
Mises en garde cliniques
- Mise en garde majeure · Ne pas appliquer sur une peau ou muqueuse lésée, érodée, brûlée ou infectée, ni sur de grandes surfaces : l’absorption systémique et la toxicité augmentent. Éviter les yeux et ne pas dépasser la dose ou la durée. — CIMA DERMOVAGISIL PICOR 20 mg/g crema vaginal, registro 62878
- Une irritation, une sensation de brûlure, un œdème ou une réaction allergique au site d’application peuvent rarement survenir ; arrêter et demander conseil si ces effets apparaissent. — CIMA DERMOVAGISIL PICOR 20 mg/g crema vaginal, registro 62878
- L’huile de ricin sulfonée et le parfum contenant de l’alcool benzylique, du benzoate de benzyle, du cinnamaldéhyde, de l’alcool cinnamylique, du citral, du citronellol, du géraniol, du limonène et du linalol peuvent provoquer des réactions allergiques cutanées. — CIMA DERMOVAGISIL PICOR 20 mg/g crema vaginal, registro 62878
Grossesse et allaitement
Pendant la grossesse ou l’allaitement, n’utiliser que sur avis médical après évaluation des bénéfices et des risques ; la fraction absorbée traverse le placenta et passe dans le lait.
Bibliographie récente (PubMed)
Managing postoperative pain in patients with obesity is challenging. Although multimodal analgesia has proved effective for pain relief, the specific impacts of different nonopioid i.v. analgesics and adjuvants on these patients are not well-defined. This study aims to assess the effectiveness of nonsteroidal antiinflammatory drugs, paracetamol, ketamine, α-2 adrenergic receptor agonists, lidocaine, magnesium, and oral gabapentinoids in reducing perioperative opioid consumption and, secondarily, in mitigating the occurrence of general and postoperative pulmonary complications (POPCs), nausea, vomiting, PACU length of stay (LOS), and hospital LOS among surgical patients with obesity. A systematic review and network meta-analysis was performed. PubMed, Scopus, Web of Science, CINAHL, and EMBASE were searched. Only English-language RCTs investigating the use of nonopioid analgesics and adjuvants in adult surgical patients with obesity were included. The quality of evidence and certainty were assessed using the RoB 2 tool and GRADE framework, respectively. In total, 37 RCTs involving 3602 patients were included in the quantitative analysis. Compared with placebo/no intervention or a comparator, dexmedetomidine, ketamine, lidocaine, magnesium, and gabapentin significantly reduced postoperative opioid consumption after surgery. Ketamine/esketamine also significantly reduced POPCs. Ibuprofen, dexmedetomidine, and lidocaine significantly reduced postoperative nausea, whereas dexmedetomidine, either alone or combined with pregabalin, and lidocaine reduced postoperative vomiting. Dexmedetomidine significantly reduced PACU LOS, whereas both paracetamol and lidocaine reduced hospital LOS. Intravenous nonopioid analgesics and adjuvants are crucial in multimodal anaesthesia, reducing opioid consumption and enhancing postoperative care in adult surgical patients with obesity. CRD42023399373 (PROSPERO). Lidocaine concentrations in milk during continuous IV infusion, epidural admini
Over the last few years, numerous reports have lauded the efficacy of articaine hydrochloride as a local anesthetic (LA) in dental procedures. Numerous studies have shown that articaine outperforms lidocaine in various aspects of dental treatment, leading to its widespread adoption in both adults and children. Despite the publications of comparative studies, there remains a dearth of systematic reviews examining the adverse effects of articaine versus lidocaine in randomized controlled trials. The aim was to assess the available research on the adverse effects of articaine and lidocaine in pediatric dentistry. A comprehensive search was conducted on Cochrane Library, Pubmed, Chinese Biomedical Literature Database (CBM), Embase, Web of Science and China National Knowledge Infrastructure (CNKI). Randomized controlled trials (RCT) that compared articaine with lidocaine in pediatric dentistry were included. Methodological quality assessment and risk of bias were determined for each of the included studies. The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach was used to assess the strength of evidence for every research. A total of 333 studies were identified through electronic searches. After conducting primary and secondary assessments, eight studies were included for the final qualitative analysis. We found no difference in the probability of adverse reactions between articaine and lidocaine after treatment in pediatric patients (risk ratio (RR) = 1.08, 95% confidence interval (CI) (0.54-2.15), p = 0.83). However, a high heterogeneity was reported among the outcomes in the investigated studies (I2 = 57%), and the strength of the evidence was classified as "moderate" based on the GRADE approach. Besides, we found no significant difference in the probability of postoperative pain, postoperative soft tissue injury and edema between articaine and lidocaine in pediatric patients following treatment. There was moderate quality evidence s
Epistaxis is a very common presentation in the emergency department (ED), accounting for approximately 1 in 200 ED visits in the United States. Currently, standard practice includes the initial use of topical anesthetics and vasoconstrictors, followed by more invasive treatments such as nasal packing, cauterization or surgical ligation for refractory cases. Over the years several studies have investigated the potential use of topical Tranexamic Acid (TXA) in the management of epistaxis. We have conducted a meta-analysis to assess the efficacy of topical TXA versus other standard practices or placebo in the management of epistaxis. PubMed and Scopus databases were searched from inception to April 2021. We included randomized controlled trials and observational studies investigating the efficacy of TXA in bleeding cessation in epistaxis in adults. The primary outcome measured was the prevalence of bleeding cessation after treatment at first assessment. Other outcomes were bleeding reoccurrence between 24 and 72 h and at 7-8 days. A random-effects model was used to estimate odds ratio (OR) for outcomes. A total of eight studies were included in the analysis, including seven randomized trials and one retrospective study. We included a total of 1299 patients, 596 (46%) received TXA while 703 (54%) received control treatment (placebo, lidocaine plus vasoconstrictors or local anesthetics). Patients who were treated with TXA were 3.5 times (OR 3.5, 95% CI 1.3-9.7) more likely to achieve bleeding cessation at the first assessment. Patients treated with TXA had 63% (OR 0.37, 95% CI 0.20-0.66) less likelihood of returning due to rebleeding at 24-72 h. Topical TXA is associated with better bleeding cessation rates after treatment compared to the standard practices. This sheet is about exposure to lidocaine in pregnancy and while breastfeeding. This information is based on publishedresearch studies. It should not take the place of medical care and advice from your healthcare pro